(RTTNews) - New research from Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY) suggests that their GLP-1 drugs may slow down certain biological signs of aging by two to four years.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.